9 A prospective, randomized, non-inferiority trial to determine the safety and efficacy of the biolimus A9™ drug coated balloon for the treatment of in-stent restenosis: first-in-man trial (REFORM)
Seán Fitzgerald(Discovery Laboratories (United States)), RA Byrne, Samuel Copt, BP Traynor, Jochen Wöhrle, Himanshu Rai(Deutsches Herzzentrum München), Peter O’Kane(Royal Bournemouth Hospital), Darren Mylotte(University Hospital Galway), Bernardo Cortese, Diane Schuette(Biosensors International Group (Singapore)), J-Y Hahn(Samsung Medical Center), MC Morice(Cardiovascular European Research Center), Jasper Trevelyan(Worcestershire Royal Hospital), Ralph Tölg(Segeberger Kliniken), Manel Sabaté(Hospital Clínico San Carlos), KG Oldroyd(Biosensors International Group (Singapore)), Fernándo Alfonso(Hospital Universitario de La Princesa)
Cited by 1
Related Papers
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
|The Lancet|2007|1.4k
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction
|New England Journal of Medicine|2022|566
Optical coherence tomography in coronary atherosclerosis assessment and intervention
|Nature Reviews Cardiology|2022|397
Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis
|The Lancet|2015|347
OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions
|New England Journal of Medicine|2023|341